EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Dermatopathological Findings of an Erythema Multiforme‐Like Drug Eruption During Enfortumab Vedotin Plus Pembrolizumab Therapy for Metastatic Urothelial Carcinoma: A Case Report

Ryunosuke Murofushi iD, Yoichiro Kato, Takashi Seo, Kazuhiro Iwasaki, Maki Goto, Nobuhiro Monma, Shigekatsu Maekawa, Wataru Obara iD

Clinical Case Reports · 2026-04 · 14 (4)

DOI: 10.1002/ccr3.71950 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Clinical Case Reports, online erschienen am 03.04.2026. Verfasst von Ryunosuke Murofushi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology Morioka Red Cross Hospital Morioka Japan. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The combination therapy of enfortumab vedotin and pembrolizumab (EV+Pem) is effective for metastatic urothelial carcinoma. However, the dermatopathological findings for treatment‐related adverse events, particularly skin disorders, often remain unclear. We report a 69‐year‐old male with metastatic renal pelvic cancer who developed a Common Terminology Criteria for Adverse Events (CTCAE) grade 3 erythema multiforme–like drug eruption during EV+Pem on day 8 of cycle 3. Dermatopathological findings by skin biopsy at onset and remission were evaluated with immunohistochemistry, demonstrating improvement in proliferative activity (mitotic figures/Ki‐67) in parallel with clinical improvement. Peripheral blood tests showed parallel changes in monocytes and eosinophils with the clinical course of the eruption. Both agents were temporarily discontinued and systemic corticosteroids were initiated, followed by tapering. EV was resumed with two‐step dose reduction, while pembrolizumab was resumed at the full dose. However, grade 2 rash recurred and was controlled with prednisolone escalation and subsequent tapering, allowing continued therapy with further EV dose reduction. The metastatic lesions have remained in partial response (PR). The evaluation of dermatopathological findings at onset and remission is important in managing skin disorders associated with the combination therapy of EV and pembrolizumab in patients with metastatic urothelial carcinoma.

Schlagwörter

Stichwörter der Autor:innen

dermatopathological findingsenfortumab vedotin plus pembrolizumaberythema multiforme–like eruptionmetastatic urothelial carcinoma

Autor:innen und Institutionen

  • Department of Urology Morioka Red Cross Hospital Morioka Japan.
  • Department of Urology Iwate Medical University Shiwa-gun Japan.
  • Department of Dermatology Morioka Red Cross Hospital Morioka Japan.
  • Department of Pathology Morioka Red Cross Hospital Morioka Japan.

ORCID-Profile: Ryunosuke Murofushi, Wataru Obara

Zitieren

APA

Murofushi, R., Kato, Y., Seo, T., Iwasaki, K., Goto, M., Monma, N., Maekawa, S., & Obara, W. (2026). Dermatopathological Findings of an Erythema Multiforme‐Like Drug Eruption During Enfortumab Vedotin Plus Pembrolizumab Therapy for Metastatic Urothelial Carcinoma: A Case Report. Clinical Case Reports, 14(4). https://doi.org/10.1002/ccr3.71950

Vancouver

Murofushi R, Kato Y, Seo T, Iwasaki K, Goto M, Monma N, et al. Dermatopathological Findings of an Erythema Multiforme‐Like Drug Eruption During Enfortumab Vedotin Plus Pembrolizumab Therapy for Metastatic Urothelial Carcinoma: A Case Report. Clinical Case Reports. 2026;14(4). doi:10.1002/ccr3.71950

BibTeX
@article{Murofushi2026,
  author = {Murofushi, Ryunosuke and Kato, Yoichiro and Seo, Takashi and Iwasaki, Kazuhiro and Goto, Maki and Monma, Nobuhiro and Maekawa, Shigekatsu and Obara, Wataru},
  title = {Dermatopathological Findings of an Erythema Multiforme‐Like Drug Eruption During Enfortumab Vedotin Plus Pembrolizumab Therapy for Metastatic Urothelial Carcinoma: A Case Report},
  journal = {Clinical Case Reports},
  year = {2026},
  volume = {14},
  number = {4},
  doi = {10.1002/ccr3.71950}
}
Kostenlos starten →